Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Varenicline for smoking cessation in patients with mild-to-moderate chronic obstructive pulmonary disease
2005-004412-70Phase 3Completed
- Sponsor
- Pfizer
- Start
- Sep 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in nicotine dependence and chronic obstructive pulmonary disease (COPD) comparing Varenicline with Placebo (2 arms). Primary endpoint: 4-week continuous quit rate during Weeks 9-12. Started Sep 2007; status: completed.
02
Drugs
varenicline
03
Conditions
nicotine dependencechronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2005-004412-70.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004412-70.